Derakhshan Mahnaz, Ansarian Hamid Reza, Ghomshei Mory
Conovita Technologies Inc., Winnipeg, Canada.
Queen Mary University of London Alumni, London, UK.
J Int Med Res. 2020 Sep;48(9):300060520958594. doi: 10.1177/0300060520958594.
Coronavirus disease 2019 (COVID-19) shows a wide range of severity, ranging from an asymptomatic presentation to a severe illness requiring intensive care unit admission. Identification of a strategy to manage the severity of this disease will not only help to reduce its case fatality but also help to remove some of the burden from the already overwhelmed health care systems. While successful management of symptoms in general is important, identifying measures to modify the severity of the illness is a key factor in the fight against this pandemic.
This paper presents a short literature review to suggest a new treatment modality for COVID-19.
COVID-19 is less severe and rarely fatal in children than in adults, which could be caused by greater fluctuations of plasma epinephrine in children. Our literature survey endorses this hypothesis according to both the epidemiological and immunological findings.
Application of epinephrine pulses with a specific amplitude may be considered an intervention to minimize the severity of COVID-19.
2019冠状病毒病（COVID-19）表现出广泛的严重程度，从无症状表现到需要入住重症监护病房的严重疾病。确定一种管理该疾病严重程度的策略不仅有助于降低其病死率，还有助于减轻已经不堪重负的医疗系统的部分负担。虽然总体上成功管理症状很重要，但确定改变疾病严重程度的措施是抗击这一疫情的关键因素。
本文进行简短的文献综述，以提出一种针对COVID-19的新治疗方式。
COVID-19在儿童中比在成人中症状较轻且很少致命，这可能是由儿童血浆肾上腺素的较大波动所致。我们的文献调查根据流行病学和免疫学研究结果支持了这一假设。
应用特定幅度的肾上腺素脉冲可被视为一种将COVID-19严重程度降至最低的干预措施。
